Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 14/20 | 1.00 |
| ▸ | RORC | P51449 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KHK | P50053 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4726596 | 0.89 | NPY5R (1.00) | NPY5RRORCKDM4EMAPTMEN1 | |
| SCHEMBL6173715 | 0.84 | NPY5R (1.00) | NPY5RRORCKHK | |
| SCHEMBL4728842 | 0.82 | NPY5R (0.83) | NPY5RRORCKDM4EMAPTMEN1 | |
| SCHEMBL6169139 | 0.81 | NPY5R (1.00) | NPY5RRORCKDM4EMAPTMEN1 | |
| SCHEMBL7963351 | 0.79 | NPY5R (1.00) | NPY5RRORCKDM4EMAPTMEN1 | |
| SCHEMBL4728615 | 0.78 | NPY5R (0.78) | NPY5RRORCKDM4EMAPTMEN1 | |
| SCHEMBL6172294 | 0.77 | NPY5R (0.79) | NPY5RRORCKDM4EMAPTMEN1 | |
| SCHEMBL6168266 | 0.77 | NPY5R (1.00) | NPY5RRORCKDM4EMAPTMEN1 | |
| SCHEMBL6172193 | 0.76 | NPY5R (0.79) | NPY5RKDM4EMAPTMEN1LMNA | |
| SCHEMBL4730104 | 0.75 | NPY5R (0.67) | NPY5RRORCKDM4EMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958347-B2 | Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists | PFIZER INC. (US) | 2005-10-25 | — | — | US | claimed |
| EP-1578728-A1 | 5-AMINOPHENANTHRIDINE DERIVATIVES AS NPY-5 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| WO-2004054981-A1 | 5-AMINOPHENANTHRIDINE DERIVATIVES AS NPY-5 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2004-07-01 | — | — | WO | claimed |
| US-20040122038-A1 | NPY-5 antagonists | PFIZER INC | 2004-06-24 | — | — | US | claimed |
| US-6958347-B2 | Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists | PFIZER INC. (US) | 2005-10-25 | — | — | US | disclosed |
| EP-1578728-A1 | 5-AMINOPHENANTHRIDINE DERIVATIVES AS NPY-5 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004054981-A1 | 5-AMINOPHENANTHRIDINE DERIVATIVES AS NPY-5 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20040122038-A1 | NPY-5 antagonists | PFIZER INC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122038-A1 | NPY-5 antagonists | NPY5R, NPY1R, NPY2R | NPY5R 1/4885RORC 987/4885KDM4E 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.